Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xylarex
- Development stage
- Unknown
- Lead developer
- Azurity Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xylarex is a branded, non-antibiotic oral solution containing the sugar alcohol xylitol, developed for the dietary management of recurrent acute otitis media (ear infections) in children. It is intended for daily administration to reduce the frequency of ear infections, leveraging xylitol’s ability to interfere with the growth and adherence of otitis-associated pathogens in the nasopharynx and middle ear while avoiding antibiotic exposure.[7][11] As a medical food–type product rather than a conventional prescription drug, Xylarex is positioned for chronic pediatric use under medical supervision in children with a history of recurrent acute otitis media.[7][11]
- Brand names
- Xylarex
Beyond the preview
Go deeper on Xylarex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xylarex.